Viralytics

Last updated

Viralytics Ltd [1]
Industry Biotechnology
Founded2006
HeadquartersSydney
Key people
 Paul A. Hopper
Non-Executive chairman)
Malcolm McColl
(chief executive officer)
Darren Shafren
(Chief Scientific Officer)
ProductsCavatak, an oncylytic virus
Website www.viralytics.com

Viralytics Ltd is an Australian biotechnology company working in the field of oncolytic viruses, that is, viruses that preferentially infect and kill cancer cells. The company's oncolytic virus product, called Cavatak, is currently in clinical trials in metastatic melanoma and other cancers. The drug was granted Orphan Drug status in advanced melanoma in December 2005. [2]

Contents

Corporate history

Around 1999 a team led by the virologist Professor Darren Shafren at the University of Newcastle in Australia established that a Coxsackievirus called Coxsackievirus A21 was an oncolytic virus, in addition to being a common-cold virus causing mild upper respiratory tract infections. [3] Shafren filed for patent protection over the use of the virus in oncology [4] and the University of Newcastle subsequently formed a spin-out company called ViroTarg Pty Ltd. An ASX-listed biotech company called Psiron began to fund development of the ViroTarg project in June 2004 [5] and in December 2006 acquired the Virotarg intellectual property. Psiron changed its name in the process to Viralytics to reflect the fact that oncolytic viruses were now its core focus. [6] Shafren's wild-type Coxsackievirus A21, which Viralytics called Cavatak, was trialled in a Phase I in melanoma between 2007 and 2010 and in 2012 the product entered a Phase II trial in advanced melanoma called 'CALM', short for CAvatak in Late Stage Melanoma'. This trial took place under an Investigational New Drug application. The trial completed in 2015 with favourable results and multiple trials are now underway to establish various indications for Cavatak.

In 2018, [7] Veralytics became a wholly-owned subsidiary of Merck & Co. [8]

Viralytics stock is publicly traded on the ASX under the code VLA. In the US its ADRs have traded OTC since October 2006 [9] and on OTCQX under the code VRACY since August 2013. [10] The ratio of ADRs to the ordinary shares is 30:1.

Board of directors

Viralytics' Non-Executive chairman is Paul Hopper, an Australian bioentrepreneur based in Sydney who has been a director since September 2008 [11] and chairman since November 2008. [12] The company's CEO is Dr Malcolm McColl, a former executive of the major Australian pharmaceutical company CSL and the biotech company Starpharma who joined the company in January 2013. [13]

Locations

Viralytics' is headquartered in the City Mutual Building, an art deco icon in the Sydney CBD located at 66 Hunter Street. Darren Shafren has a laboratory in Newcastle.

Cavatak

Cavatak is the trade name for a preparation of wild-type Coxsackievirus A21, as manufactured by Viralytics. Within the Picornaviradae family of viruses, Coxsackievirus A21 is a member of the Human enterovirus C species. The virus consists of a single positive-stranded RNA genome within a capsid of approximately 28 nm in diameter. The virus is known to utilise the viral entry receptor ICAM-1 as its primary entry receptor, with DAF as a co-receptor to infect host cells. [14]

Mechanism of action

The firm argues that Cavatak has a dual mechanism of action. As well as oncolysis through the preferential targeting of cells that over-express the molecules ICAM-1 and/or DAF compared to normal cells, there is also an immunological involvement in which the infection promotes tumour inflammation, which in turn prompts the patient's immune system to attack the infected cancer cells. [15]

Pre-clinical evidence of efficacy

Shafren et al. first published data showing that Cavatak could destroy malignant melanoma cells in the journal Clinical Cancer Research in January 2004. [16] A June 2005 paper in the International Journal of Oncology showed that this effect worked as well for melanoma exhibiting a highly vascular phenotype. [17] In April 2007, in a paper in the British Journal of Haematology , the Shafren lab showed that Cavatak could work in multiple myeloma [18] and over the next two years papers in The Prostate (May 2008) [19] and Breast Cancer Research and Treatment (January 2009) [20] suggested similar pre-clinical efficacy in prostate and breast cancer respectively. What these cancers have in common is that they all have high levels of ICAM-1 expression.

2007–2011: Early clinical work

In January 2010 Viralytics reported favourable results from a nine patient Phase I trial of Cavatak in Stage IV melanoma patients (ClinicalTrials.gov identifier NCT00438009) where the virus was administered intratumourally. In this trial, which was initiated in May 2007 [21] but was not completed until 2009, all patients were given two Cavatak doses of the same size 48 hours apart into a single cutaneous melanoma lesion. Three patients received a low dose, three a middle dose and three a high dose.

  • Five of the nine patients, or 55.6%, experienced transient/stable reductions in injected tumour volume or tumour stabilization. No objective responses were observed, however, two patients displayed stable disease as assessed by RECIST following CT scan evaluation; [22]
  • Two of the patients that had enjoyed large reductions in lesion volume registered elevated levels of serum GM-CSF, suggesting that there had been an anti-tumour immune response. [23]

These results were presented at the May 2011 Annual Meeting of the American Society of Clinical Oncology, held that same year at Chicago.

2012–2015: The CALM study

The Phase II CALM study (ClinicalTrials.gov identifier NCT01227551) took a considerable period of time for Viralytics to initiate – the pre-IND meeting with the FDA was held in June 2010 [24] and Viralytics lodged its IND in November 2010, [25] however the trial wasn't cleared until June 2011. [26] This meant that the study didn't dose its first patient until after January 2012. [27] However this open-label trial was eventually able to evaluate 57 patients with stage IIIc or stage IV melanoma. Each evaluated patient received 10 intratumoural injections of Cavatak over 18 weeks. The dose level was 3x108 TCID50 virus with the investigators measuring response rates as well as Progression Free Survival at 6 months, and tracking the immune response of the patient. The trial was one of the first in the world to make use of the new Immune-Related Response Criteria.

  • Immune-related Progression Free Survival. CALM's Primary Endpoint, reached in September 2013, was 10 patients from a total of 54 evaluable patients experiencing immune-related Progression Free Survival (irPFS) at six months, that is, their tumour had not 'progressed' (i.e. worsened) as determined by the Immune-Related Response Criteria. [28] In September 2014 Viralytics was able to report a 39% irPFS rate at six months (22 of 57 evaluable patients). [29]
  • Survival and Response Rate. In June 2015 final survival data from CALM showed a 73% one-year Overall Survival rate in the CALM patients (43 out of 57 patients). The Overall Response Rate in the study from the final data was 28% (8 complete and 8 partial responses out of 57 patients). The Durable Response Rate, where the response continued more than six months, was 21% (12 out of 57 patients). The investigators also noted activity in non-injected distant lesions including lung and liver metastases. [30]

Current clinical trials

  • CALM Extension Study. This Phase II study (ClinicalTrials.gov identifier NCT01636882) is giving patients from the CALM study who have not experienced an immune-related progression event another nine intra-tumoural Cavatak injections in order to allow biopsies taken from both injected and non-injected melanoma lesions. These biopsies are being examined with a view to better understanding how Cavatak triggers an immune response. Data from 13 evaluated patients in the study, reported in June 2015, has shown tumour-infiltrating lymphocytes and PD-L1 upregulation in the area of the lesions, the latter phenomenon suggesting that Cavatak may be synergistic with checkpoint inhibitors. [30]
  • STORM (Systemic Treatment Of Resistant Metastatic Disease). This Phase I study (ClinicalTrials.gov identifier NCT02043665), which commenced in March 2014, [31] is recruiting patients with treatment-resistant Non-Small Cell Lung Cancer, castration-resistant prostate cancer, and treatment-resistant melanoma and bladder cancer to receive intravenous injections of Cavatak. Under a November 2015 agreement with Merck & Co. the lung and bladder cancer patients will receive Cavatak in conjunction with the checkpoint inhibitor drug Keytruda. [32]
  • CANON CAvatak in NON-Muscle Invasive Bladder Cancer.) This Phase I study (ClinicalTrials.gov identifier NCT02316171), which commenced in the UK in January 2014, is evaluating Cavatak in superficial bladder cancer. [33] [34] This two-part, open label dose escalation study will evaluate the safety and optimal dose of Cavatak as a monotherapy and in combination with the standard of care drug mitomycin C.
  • MITCI (Melanoma Intra-Tumoural Cavatak and Ipilimumab). This Phase I study (ClinicalTrials.gov identifier NCT02307149), initiated in December 2014, will see intra-tumoural Cavatak combined with the Bristol-Myers Squibb drug Yervoy, another checkpoint inhibitor, in metastatic melanoma. [35]
  • CAPRA (CAvatak and PembRolizumab in Advanced Melanoma). This Phase I study (ClinicalTrials.gov identifier NCT02565992), which initiated in September 2015, [36] will see intra-tumoural Cavatak combined with Keytruda in metastatic melanoma.

See also

Related Research Articles

A cancer vaccine is a vaccine that either treats existing cancer or prevents development of cancer. Vaccines that treat existing cancer are known as therapeutic cancer vaccines or tumor antigen vaccines. Some of the vaccines are "autologous", being prepared from samples taken from the patient, and are specific to that patient.

<span class="mw-page-title-main">Cancer immunotherapy</span> Artificial stimulation of the immune system to treat cancer

Cancer immunotherapy is the stimulation of the immune system to treat cancer, improving on the immune system's natural ability to fight the disease. It is an application of the fundamental research of cancer immunology and a growing subspecialty of oncology.

An oncolytic virus is a virus that preferentially infects and kills cancer cells. As the infected cancer cells are destroyed by oncolysis, they release new infectious virus particles or virions to help destroy the remaining tumour. Oncolytic viruses are thought not only to cause direct destruction of the tumour cells, but also to stimulate host anti-tumour immune system responses. Oncolytic viruses also have the ability to affect the tumor micro-environment in multiple ways.

Virotherapy is a treatment using biotechnology to convert viruses into therapeutic agents by reprogramming viruses to treat diseases. There are three main branches of virotherapy: anti-cancer oncolytic viruses, viral vectors for gene therapy and viral immunotherapy. These branches use three different types of treatment methods: gene overexpression, gene knockout, and suicide gene delivery. Gene overexpression adds genetic sequences that compensate for low to zero levels of needed gene expression. Gene knockout uses RNA methods to silence or reduce expression of disease-causing genes. Suicide gene delivery introduces genetic sequences that induce an apoptotic response in cells, usually to kill cancerous growths. In a slightly different context, virotherapy can also refer more broadly to the use of viruses to treat certain medical conditions by killing pathogens.

<span class="mw-page-title-main">Tumor-infiltrating lymphocytes</span>

Tumor-infiltrating lymphocytes (TIL) are white blood cells that have left the bloodstream and migrated towards a tumor. They include T cells and B cells and are part of the larger category of ‘tumor-infiltrating immune cells’ which consist of both mononuclear and polymorphonuclear immune cells, in variable proportions. Their abundance varies with tumor type and stage and in some cases relates to disease prognosis.

Tigatuzumab (CS-1008) is a monoclonal antibody for the treatment of cancer. As of October 2009, a clinical trial for the treatment of pancreatic cancer, Phase II trials for colorectal cancer, non-small cell lung cancer, and ovarian cancer have been completed.

Glembatumumab vedotin is an antibody-drug conjugate (ADC) that targets cancer cells expressing transmembrane glycoprotein NMB (GPNMB).

Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses.

Pelareorep is a proprietary isolate of the unmodified human reovirus being developed as a systemically administered immuno-oncological viral agent for the treatment of solid tumors and hematological malignancies. Pelareorep is an oncolytic virus, which means that it preferentially lyses cancer cells. Pelareorep also promotes an inflamed tumor phenotype through innate and adaptive immune responses. Preliminary clinical trials indicate that it may have anti-cancer effects across a variety of cancer types when administered alone and in combination with other cancer therapies.

JX-594 is an oncolytic virus is designed to target and destroy cancer cells. It is also known as Pexa-Vec, INN pexastimogene devacirepvec) and was constructed in Dr. Edmund Lattime's lab at Thomas Jefferson University, tested in clinical trials on melanoma patients, and licensed and further developed by SillaJen.

<span class="mw-page-title-main">Nivolumab</span> Cancer drug

Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer. This includes melanoma, lung cancer, malignant pleural mesothelioma, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colon cancer, esophageal squamous cell carcinoma, liver cancer, gastric cancer, and esophageal or gastroesophageal junction (GEJ) cancer. It is used by slow injection into a vein.

<span class="mw-page-title-main">Abscopal effect</span>

The abscopal effect is a hypothesis in the treatment of metastatic cancer whereby shrinkage of untreated tumors occurs concurrently with shrinkage of tumors within the scope of the localized treatment. R.H. Mole proposed the term “abscopal” in 1953 to refer to effects of ionizing radiation “at a distance from the irradiated volume but within the same organism.”

<span class="mw-page-title-main">Talimogene laherparepvec</span> Gene therapy medication

Talimogene laherparepvec, sold under the brand name Imlygic, is a biopharmaceutical medication used to treat melanoma that cannot be operated on; it is injected directly into a subset of lesions which generates a systemic immune response against the recipient's cancer. The final four year analysis from the pivotal phase 3 study upon which TVEC was approved by the FDA showed a 31.5% response rate with a 16.9% complete response (CR) rate. There was also a substantial and statistically significant survival benefit in patients with earlier metastatic disease and in patients who hadn't received prior systemic treatment for melanoma. The earlier stage group had a reduction in the risk of death of approximately 50% with one in four patients appearing to have met, or be close to be reaching, the medical definition of cure. Real world use of talimogene laherparepvec have shown response rates of up to 88.5% with CR rates of up to 61.5%.

<span class="mw-page-title-main">Oncolytic herpes virus</span>

Many variants of herpes simplex virus have been considered for viral therapy of cancer; the early development of these was thoroughly reviewed in the journal Cancer Gene Therapy in 2002. This page describes the most notable variants—those tested in clinical trials: G207, HSV1716, NV1020 and Talimogene laherparepvec. These attenuated versions are constructed by deleting viral genes required for infecting or replicating inside normal cells but not cancer cells, such as ICP34.5, ICP6/UL39, and ICP47.

<span class="mw-page-title-main">Pembrolizumab</span> Pharmaceutical drug used in cancer treatment

Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is given by slow injection into a vein.

Eftilagimod alpha is a large-molecule cancer drug being developed by the clinical-stage biotechnology company Immutep. Efti is a soluble version of the immune checkpoint molecule LAG-3. It is an APC Activator used to increase an immune response to tumors, and is administered by subcutaneous injection. Efti has three intended clinical settings:

GL-ONC1 is an investigational therapeutic product consisting of the clinical grade formulation of the laboratory strain GLV-1h68, an oncolytic virus developed by Genelux Corporation. GL-ONC1 is currently under evaluation in Phase I/II human clinical trials in the United States and Europe.

Ieramilimab is a monoclonal antibody being developed by Novartis for the treatment of cancer. The antibody targets the immune checkpoint LAG-3, which is expressed on T cells and tends to down-regulate an immune response. In a June 2015 presentation Novartis management indicated that 'dosing is imminent' for the first clinical trials of LAG525.

Imugene Ltd is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Imugene's unique platform technologies seeks to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.

Paul A. Hopper is an Australian bioentrepreneur who has been associated since 2003 with a number of biotechnology companies, most of them publicly traded.

References

  1. ↑ | type = Public company | traded_as = ASX:  VLA
  2. ↑ "Psiron's Cavatak received Orphan Drug Designation from the FDA" (PDF). asx.com.au. 21 December 2015. Retrieved 4 December 2015.
  3. ↑ Magee WE; Miller OV. (1 September 1970). "Individual variability in antibody response of human volunteers to infection of the upper respiratory tract by coxsackie A21 virus". J Infect Dis. 122 (3): 127–38. doi:10.1093/infdis/122.3.127. PMID   4317757.
  4. ↑ WOapplication 2001037866,Darren Shafren,"A method of treating a malignancy in a subject and a pharmaceutical composition for use in same",published 2001-05-31, assigned to The University of Newcastle
  5. ↑ "Psiron signs MOU and moves to a cancer therapy focus" (PDF). asx.com.au. 22 June 2004. Retrieved 4 December 2015.
  6. ↑ "Change of Name to Viralytic Ltd" (PDF). asx.com.au. 21 December 2006. Retrieved 4 December 2015.
  7. ↑ Birney, Matt (8 December 2021). "Radiopharm's research elevated in prestigious publication". The West Australian . Retrieved 7 January 2022. In 2018 Hopper sold another one of his successful companies, Viralytics, to Merck for a healthy $500 million.
  8. ↑ Hirschler, Ben (21 February 2018). "Merck to buy virus-based cancer drug firm Viralytics for $394 million". Reuters . Retrieved 7 January 2022.
  9. ↑ "Commencement of ADR trading" (PDF). asx.com.au. 13 October 2006. Retrieved 4 December 2015.
  10. ↑ "Viralytics commences trading on US OTCQX marketplace" (PDF). asx.com.au. 5 August 2013. Retrieved 4 December 2015.
  11. ↑ "Appointment of Paul Hopper as Non-Executive Director" (PDF). asx.com.au. 4 September 2008. Retrieved 3 December 2015.
  12. ↑ "Viralytics restructures Board and Management" (PDF). asx.com.au. 23 October 2008. Retrieved 3 December 2015.
  13. ↑ "Dr Malcolm McColl commences as Chief Executive Officer" (PDF). asx.com.au. 23 January 2013. Retrieved 3 December 2015.
  14. ↑ Shafren DR, Dorahy DJ, Ingham RA, Burns GF, Barry RD (1997). "Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry". J Virol. 71 (6): 4736–43. doi:10.1128/JVI.71.6.4736-4743.1997. PMC   191695 . PMID   9151867.
  15. ↑ Shafren D, Quah M, Wong Y, Andtbacka R, Kaufman H, Au G (1 June 2005). "Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model". J Immunother Cancer. 2 (Suppl 3): P125. doi: 10.1186/2051-1426-2-S3-P125 . PMC   4288429 .
  16. ↑ Shafren DR, Au GG, Nguyen T, Newcombe NG, Haley ES, Beagley L, et al. (2004). "Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21". Clin Cancer Res. 10 (1 Pt 1): 53–60. doi:10.1158/1078-0432.ccr-0690-3. PMID   14734451.
  17. ↑ Au GG; Lindberg AM; Barry RD; Shafren DR. (1 June 2005). "Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21". Int J Oncol. 26 (6): 1471–6. doi:10.3892/ijo.26.6.1471. PMID   15870858.
  18. ↑ Au GG, Lincz LF, Enno A, Shafren DR (2007). "Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma". Br J Haematol. 137 (2): 133–41. doi: 10.1111/j.1365-2141.2007.06550.x . PMID   17391493. S2CID   28620351.
  19. ↑ Berry LJ, Au GG, Barry RD, Shafren DR (2008). "Potent oncolytic activity of human enteroviruses against human prostate cancer". Prostate. 68 (6): 577–87. doi:10.1002/pros.20741. PMID   18288643. S2CID   2129777.
  20. ↑ Skelding KA, Barry RD, Shafren DR (2009). "Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21". Breast Cancer Res Treat. 113 (1): 21–30. doi:10.1007/s10549-008-9899-2. hdl: 1959.13/924955 . PMID   18256929. S2CID   22155682.
  21. ↑ "First Patient Enrolled in Viralytics' Phase I Melanoma Cancer Trial With Cavatak" (PDF). asx.com.au. 24 May 2007. Retrieved 4 December 2015.
  22. ↑ "Melanoma Phase I Clinical Trial Report Completed" (PDF). asx.com.au. 19 January 2010. Retrieved 4 December 2015.
  23. ↑ "Chief Scientific Officer's Presentation at the International Melanoma Conference" (PDF). asx.com.au. 4 November 2010. Retrieved 4 December 2015.
  24. ↑ "US FDA Pre-IND Meeting Update" (PDF). asx.com.au. 25 June 2010. Retrieved 4 December 2015.
  25. ↑ "Investigational New Drug Application Lodged With the FDA" (PDF). asx.com.au. 3 November 2010. Retrieved 4 December 2015.
  26. ↑ "Allowance of FDA Investigational New Drug (IND) Application for Cavatak Phase II Melanoma Trial" (PDF). asx.com.au. 27 June 2011. Retrieved 4 December 2015.
  27. ↑ "First Patients Commence Cavatak Injections in Phase II Clinical Trial" (PDF). asx.com.au. 19 January 2012. Retrieved 4 December 2015.
  28. ↑ "Primary Endpoint Achieved in Cavatak Phase II Melanoma Trial" (PDF). asx.com.au. 18 September 2013. Retrieved 4 December 2015.
  29. ↑ "Updated positive data from Phase 2 trial of Cavatak in late stage melanoma" (PDF). asx.com.au. 29 September 2014. Retrieved 3 December 2015.
  30. 1 2 "Viralytics Reports Positive Final Results from Cavatak Phase II melanoma trial" (PDF). asx.com.au. 2 June 2015. Retrieved 4 December 2015.
  31. ↑ "Viralytics commences STORM phase 1/2 clinical trial" (PDF). asx.com.au. 6 March 2014. Retrieved 4 December 2015.
  32. ↑ "Viralytics and Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. to Collaborate on Combination Clinical Trial of Cavatak and Keytruda in Lung and Bladder Cancer" (PDF). asx.com.au. 6 November 2015. Retrieved 4 December 2015.
  33. ↑ "Viralytics Commences Clinical Trial of Cavatak in Bladder Cancer" (PDF). asx.com.au. 27 January 2015. Retrieved 4 December 2015.
  34. ↑ Annels, Nicola E; Mansfield, David; Arif, Mehreen; Ballesteros-Merino, Carmen; Simpson, Guy R; Denyer, Mick; Sandhu, Sarbjinder S; Melcher, Alan; Harrington, Kevin J; Davies, BronwYn; Au, Gough; Grose, Mark; Bagwan, Izhar N; Fox, Bernard A.; Vile, Richard G; Mostafid, Hugh; Shafren, Darren; Pandha, Hardev (2019). "Viral targeting of non-muscle invasive bladder cancer and priming of anti-tumour immunity following intravesical Coxsackievirus A21" (PDF). Clinical Cancer Research. 25 (19): 5818–5831. doi: 10.1158/1078-0432.CCR-18-4022 . ISSN   1078-0432. PMID   31273010. S2CID   208598278.
  35. ↑ "Viralytics to Commence Clinical Trial of Cavatak Immunotherapy Combination" (PDF). asx.com.au. 4 December 2014. Retrieved 4 December 2015.
  36. ↑ "Viralytics Initiates Clinical Trial of Cavatak in Combination with PD-1 Blocker Keytruda" (PDF). asx.com.au. 28 September 2015. Retrieved 4 December 2015.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.